


FORM 1449*  INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION <small>(Use several sheets if necessary)</small>				Docket Number: 14598-41	Application Number: 09/368,010
				Applicant: K. Kasper, et al.	
				Filing Date: August 3, 1999	Group Art Unit: 1641

US. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>MKC</i>	3,817,837	6/18/74	Rubinstein et al. (Exhibit 1)			
<i>MKC</i>	5,532,137	7/2/96	Niwa et al. (Exhibit 2)			
FOREIGN PATENT DOCUMENTS						
<i>MKC</i>	DOCUMENT NO. EPO 0293892	DATE 12/7/88	COUNTRY Niwa et al. (Exhibit 3)	CLASS	SUBCLASS	TRANSLATION
						YES
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
<i>MKC</i>	AR	Exhibit 4 is a publication, G. Wiederrecht et al., "The Mechanism of Action of FK-506 and Cyclosporin A," <u>Ann. N.Y. Acad. Sci.</u> 696:9-19 (1993).				
<i>MKC</i>	AS	Exhibit 5 is a publication, M.L. Cleary & J. Sklar, "Lymphoproliferative Disorders in Cardiac Transplant Recipients are Multiclonal Lymphomas," <u>Lancet</u> 2:49-493 (1984).				
<i>MKC</i>	AT	Exhibit 6 is a publication, L.J. Swinnen et al., "Increased Incidence of Lymphoproliferative Disorder After Immunosuppression with a Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients," <u>N. Engl. J. Med.</u> 323:1723-1728 (1990).				
<i>MKC</i>	AV	Exhibit 7 is a publication, B.Z. Katz et al., "Latent and Replicating Forms of Epstein-Barr Virus DNA and Lymphomas in Lymphoproliferative Diseases," <u>J. Infect. Dis.</u> , 160:589-598 (1989).				
<i>MKC</i>	AV	Exhibit 8 is a publication, J.S. Huston et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analog Produced in <i>Escherichia coli</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 85:5879-5883 (1988).				
<i>MKC</i>	AW	Exhibit 9 is a publication, G.T. Hermanson, "Bioconjugate Techniques" (Academic Press, San Diego, 1996), pp. 570-592.				
<i>MKC</i>	AX	Exhibit 10 is a publication, P.J. Taylor et al., "Sensitive, Specific Quantitative Analysis of Tacrolimus (FK506) in Blood by Liquid Chromatography-Electrospray Tandem Mass Spectrometry," <u>Clin. Chem.</u> 42: 279-285 (1996).				
<i>MKC</i>	AY	Exhibit 11 is a publication abstract, H.J. Jeong et al., "New Monoclonal Antibody for the Immunosuppressive Drug Tacrolimus," <u>Ther. Drug Monit.</u> 21: 444 (August 1999), Abstract No. 65.				
<i>MKC</i>	AZ	Exhibit 12 is a publication abstract, V.W. Armstrong et al., "Evaluation of an EMIT® Tacrolimus Assay: Comparison with Pentamer Formation Assay and Tacrolimus II MEIA," <u>Ther. Drug Monit.</u> 21: 448 (August 1999), Abstract No. 80.				

EXAMINER <i>Mary E. Casperley</i>	DATE CONSIDERED <i>03/01/01</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	